ReviewCurrent pharmaceutical biotechnology2012
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.
Review in Current pharmaceutical biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Guideline
- Advances in oncolytic viruses immunotherapy of hepatocellular carcinoma.Discover oncology · 2026Review
- Enhancing antitumor immunity through oncolytic viruses: advances in genetic engineering.Discover oncology · 2026Review
- Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy.Frontiers in molecular biosciences · 2023Review
- Viral vector-based gene therapies in the clinic.Bioengineering & translational medicine · 2022Review
- Emulating interactions between microorganisms and tumor microenvironment to develop cancer theranostics.Theranostics · 2022Review
- Serendipitous synergism - an exceptional response to treatment with pembrolizumab in the course of a natural immunovirotherapy: a case report and review of the literature.Therapeutic advances in medical oncology · 2022Article
- Organoid modeling of Zika and herpes simplex virus 1 infections reveals virus-specific responses leading to microcephaly.Cell stem cell · 2021Article
- Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.Journal of virology · 2021Article
- Role of immunotherapy in Ewing sarcoma.Journal for immunotherapy of cancer · 2020Review
- Developing oncolyticIranian journal of basic medical sciences · 2020Article
- Human alpha and beta herpesviruses and cancer: passengers or foes?Folia microbiologica · 2020Review
- Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.Molecular cancer therapeutics · 2019Article
- PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance.Nature communications · 2018Article
- Transcriptomic study of Herpes simplex virus type-1 using full-length sequencing techniques.Scientific data · 2018Article
- Structure of the herpes simplex virus type 2 C-capsid with capsid-vertex-specific component.Nature communications · 2018Article
- White paper on microbial anti-cancer therapy and prevention.Journal for immunotherapy of cancer · 2018Review
- A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.PLoS pathogens · 2018Article
- Oncolytic virus and PD-1/PD-L1 blockade combination therapy.Oncolytic virotherapy · 2018Review
- Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.Journal of translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Oncolytic virotherapy with mutants derived from Herpes simplex virus (HSV) type 1 exhibit significant antitumor effects in preclinical models. Several mutants have now been tested in clinical trials for a variety of cancer types, and all have been found to be safe. While there have been hints of antitumor efficacy with prolonged survival in some cases compared with historical controls, dramatic responses have been elusive. We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.